RE:Listened to the Stifel-GMP call again ...MrMugsy wrote: Very informative for new investors - Samira threw out a lot of information in a very short time. Also said, "Jonathan has stepped into the executive chairman role. He doesn't leave me alone. We have our regular calls ... does what he always does."
I'm guessing he's always guided the board in his own strategic direction - same old - same old !
Lots shared about the look and the make-up of ROW and why they chose LATAM (for its growth)
- as expected, two-thirds of the Argentinian workforce (roughly 233 people) are involved in the manufacture of drugs - on the branded generic side. Samira seems very excited about this part of the business. Seems like the golden nugget of the Grupo purchase.
As part of the multi-pronged approach, they are working on in-licensing, acquiring mature products and developing low-risk/low-expense products (the Argentinian operation re. branded generics). Also looking at bolt-on acquisitions (company or portfolio). This will be the bread and butter of their growth story.
I am assuming R&D is also in Argentina? Don't think they mentioned it specifically but it must be in Argentina. Anyone know?
This is 100% the path expected for GUD.
Slow and steady is what it takes - patient investors required - others need not apply.
Hahaha !
No one knew how they'd get here and even Samira compared the options of buying a family business vs. buying from private equity.
Private Equity was not the way she wanted to do it as it required a major clean-up.
Buying Grupo was the best of the options.
Good Luck All.
Did Samira say they see 16 % organic growth expected for 2022 ?